| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8419726 | Journal of Immunological Methods | 2010 | 8 Pages |
Abstract
This study suggests that when different DC numbers are found between two study populations, the DC activation status from both groups always needs to be verified, since a decrease in BDCA-2+ pDCs or an increase in CD11c+ mDCs or CD123+ pDCs can be due to the altered expression of these markers during activation. Given that CD11c, BDCA-1, CD123 and BDCA-2 are more abundantly expressed on blood DCs than typical activation markers like CD83, CD86 or CCR-7, the use of the ratios is an easy and reliable way to determine DC activation in whole blood assays.
Keywords
BDCATLRMDCPBMCsICAMIMDMAPC-Cy7mAbsPDCMFIFITCLPSDendritic cell activationnatural killerIscove's modified Dulbecco's mediumBlood dendritic cell antigenImiquimodinterferonIFNinterleukincoronary artery diseaseToll-like receptorDendritic cellPlasmacytoid dendritic cellperipheral blood mononuclear cellsMyeloid dendritic cellCADphycoerythrinfluorescein isothiocyanateFlow cytometrylipopolysaccharidemean fluorescence intensityMonoclonal antibodies
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Ilse Van Brussel, Emily A. Van Vré, Guido R.Y. De Meyer, Christiaan J. Vrints, Johan M. Bosmans, Hidde Bult,